News
MEDXF
3.780
-1.31%
-0.050
Weekly Report: what happened at MEDXF last week (0810-0814)?
Weekly Report · 18h ago
Medexus Pharmaceuticals reports Q2 results
Seeking Alpha · 08/10 21:33
Medexus Announces Fiscal Q1 2027 Results With Strongest Quarter of Product-Level Performance of GRAFAPEX (Treosulfan) to Date
Newsfile · 08/10 21:30
Weekly Report: what happened at MEDXF last week (0803-0807)?
Weekly Report · 08/10 09:55
Quant snapshot: Lenovo Group and Lumentum Holdings lead top-rated names as Cannae Holdings and Crescent Capital BDC Payments lag
Seeking Alpha · 08/09 13:30
Weekly Report: what happened at MEDXF last week (0727-0731)?
Weekly Report · 08/03 09:54
Medexus Schedules First Fiscal Quarter 2027 Conference Call
Newsfile · 07/30 21:30
Weekly Report: what happened at MEDXF last week (0720-0724)?
Weekly Report · 07/27 09:58
Weekly Report: what happened at MEDXF last week (0713-0717)?
Weekly Report · 07/20 09:55
Weekly Report: what happened at MEDXF last week (0706-0710)?
Weekly Report · 07/13 09:56
Weekly Report: what happened at MEDXF last week (0629-0703)?
Weekly Report · 07/06 09:59
These low-priced stocks are flashing overbought signals
Seeking Alpha · 07/03 12:05
Weekly Report: what happened at MEDXF last week (0622-0626)?
Weekly Report · 06/29 09:56
Medexus Pharmaceuticals reports Q4 results
Seeking Alpha · 06/25 22:05
Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum and Strong Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Newsfile · 06/25 22:00
Weekly Report: what happened at MEDXF last week (0615-0619)?
Weekly Report · 06/22 10:02
Quant earnings preview: Micron, BlackBerry top this week's highest-rated reports
Seeking Alpha · 06/21 13:30
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2026 Conference Call
Newsfile · 06/16 21:30
Weekly Report: what happened at MEDXF last week (0608-0612)?
Weekly Report · 06/15 10:03
Medexus Announces License and Supply Deal for UM171 Cell Therapy in Canada
Newsfile · 06/09 21:30
More
Webull provides a variety of real-time MEDXF stock news. You can receive the latest news about Medexus Pharmace through multiple platforms. This information may help you make smarter investment decisions.
About MEDXF
Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of hematology-oncology and allergy, dermatology, and rheumatology. It operates through two product portfolios: Medexus Pharma Canada and Medexus Pharma. Its lead products are IXINITY (US), GRAFAPEX (US), Trecondyv (Canada), Rupall (Canada), Rasuvo (US), Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.